| Issue Date | Title | Author(s) |
| 27-Aug-2016 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) | Zamorano, JL; Lancellotti, P; Rodriguez Muñoz, D; Aboyans, V; Asteggiano, R, et al |
| 12-Jan-2018 | A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab | Esteva, FJ; Stebbing, J; Wood-Horrall, RN; Winkle, PJ; Lee, SY, et al |
| 12-Dec-2017 | Brief report: geographic variation in EGFR mutation frequency in lung adenocarcinoma may be explained by interethnic genetic variation | Soraas, L; Stebbing, J; |
| 1-Jul-2017 | CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial | Stebbing, J; Baranau, Y; Baryash, V; Manikhas, A; Moiseyenko, V, et al |
| 16-Jan-2018 | Does molecular profiling of tumors using the Caris molecular intelligence platform improve outcomes for cancer patients? | Carter, P; Alifrangis, CC; Cereser, B; Chandrasinghe, P; Del Bel Belluz, L, et al |
| 1-Nov-2015 | HOT mutation screening in human glioblastomas | Krell, D; Mulholland, P; Stebbing, J; Tomlinson, I; Bardella, C, et al |
| 14-Feb-2017 | Lineage-specific genes are prominent DNA damage hotspots during leukemic transformation of B-cell precursors | Boulianne, B; Robinson, ME; May, PC; Castellano, L; Blighe, K, et al |
| Oct-2018 | MicroRNAs as bile-based biomarkers for pancreatic and biliary-tract cancers | Frampton, Adam; Krell, Jonathan; Stebbing, Justin; Mato Prado, Mireia; |
| 10-Feb-2016 | miR-515-5p controls cancer cell migration through MARK4 regulation | Pardo, OE; Munro, CE; Castellano, L; Hu, Y; Mauri, F, et al |
| 1-Jan-2017 | Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts | Shaw, JA; Guttery, DS; Hills, A; Fernandez-Garcia, D; Page, K, et al |
| 6-Sep-2016 | Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer | Dalgleish, AG; Stebbing, J; Adamson, DJA; Arif, SS; Bidoli, P, et al |
| Feb-2021 | SCIRT lncRNA restrains tumorigenesis by opposing transcriptional programs of tumor-initiating cells. | Zagorac, S; De Giorgio, A; Dabrowska, A; Kalisz, M; Casas-Vila, N, et al |
| 15-Jun-2019 | SSB1/SSB2 proteins safeguard B-cell development by protecting the genomes of B-cell precursors | Pfeifer, M; Brem, R; Lippert, T; Boulianne, B; Ho, HN, et al |
| 25-Jan-2017 | Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR | Castellano, L; Dabrowska, A; Pellegrino, L; Ottaviani, S; Cathcart, P, et al |
| 10-May-2018 | TGF-ß induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression | Ottaviani, S; Stebbing, J; Frampton, A; Zagorac, S; Krell, J, et al |
| 16-Jan-2018 | The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas | Carter, P; Alifrangis, CC; Chandrasinghe, P; Cereser, B; Del Bel Belluz, L, et al |
| 17-Jan-2012 | The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy | Payne, RE; Hava, NL; Page, K; Blighe, K; Ward, B, et al |